Adducin polymorphisms and the treatment of hypertension.

Abstract:

:Hypertension is an important public health problem affecting more than 50 million individuals in the USA alone. The most common form, essential hypertension, results from the complex interplay between genetic predisposition and environmental influences. Epidemiological, migration, intervention and genetic studies in humans and animals provide very strong evidence of a causal link between high salt intake and high blood pressure. One of the candidate genes for salt-sensitive hypertension is adducin. Adducin is a heterodimeric cytoskeleton protein, the three subunits of which are encoded by genes (ADD1, ADD2 and ADD3) that map to three different chromosomes. A long series of parallel studies in the Milan hypertensive rat strain model of hypertension and humans indicated that an altered adducin function might cause hypertension through enhanced constitutive tubular sodium reabsorption. An example of a prospective efficacy of pharmacogenetics and pharmacogenomics is the detection and impact of adducin polymorphisms on hypertension. In particular, the selective advantages of diuretics in preventing myocardial infarction and stroke over other antihypertensive therapies that produce a similar blood pressure reduction in carriers of the mutated adducin may support new strategies aimed at optimizing the use of new antihypertensive agents for the prevention of hypertension-associated organ damage.

journal_name

Pharmacogenomics

journal_title

Pharmacogenomics

authors

Manunta P,Citterio L,Lanzani C,Ferrandi M

doi

10.2217/14622416.8.5.465

subject

Has Abstract

pub_date

2007-05-01 00:00:00

pages

465-72

issue

5

eissn

1462-2416

issn

1744-8042

journal_volume

8

pub_type

杂志文章,评审
  • Big data in pharmacogenomics: current applications, perspectives and pitfalls.

    abstract::The efficiency of new generation sequencing methods and the reduction of their cost has led pharmacogenomics to gradually supplant pharmacogenetics, leading to new applications in personalized medicine along with new perspectives in drug design or identification of drug response factors. The amount of data generated i...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs-2018-0184

    authors: Barrot CC,Woillard JB,Picard N

    更新日期:2019-06-01 00:00:00

  • EUDRAGENE: European collaboration to establish a case-control DNA collection for studying the genetic basis of adverse drug reactions.

    abstract::Type B adverse drug reactions (ADRs) are often serious, limit the usefulness of drugs that are otherwise effective, and increase the risks of drug development as they often lead to postmarketing withdrawal. There is evidence that susceptibility to at least some Type B ADRs is under strong genetic influence. Identifyin...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/14622416.7.4.633

    authors: Molokhia M,McKeigue P

    更新日期:2006-06-01 00:00:00

  • AMPD1 polymorphism and response to regadenoson.

    abstract:AIMS: AMPD1 c.34C > T (rs17602729) polymorphism results in AMPD1 deficiency. We examined the association of AMPD1 deficiency and variability of hemodynamic response to regadenoson. SUBJECTS & METHODS:Genotyping for c.34C>T was performed in 267 patients undergoing regadenoson cardiac stress testing. RESULTS:Carriers o...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.15.116

    authors: Saab R,Zouk AN,Mastouri R,Skaar TC,Philips S,Kreutz RP

    更新日期:2015-11-01 00:00:00

  • Genetic basis of psoriasis vulgaris and its pharmacogenetic potential.

    abstract::Psoriasis vulgaris is one of the most prevalent T cell-mediated inflammatory diseases in humans. It is multifactorial in origin and shows polygenic inheritance. Systemic immunosuppressive therapies play an important role in management of severe disease cases but are associated with variable response and toxicity. With...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.1517/phgs.4.3.297.22687

    authors: Ameen M

    更新日期:2003-05-01 00:00:00

  • Genomics-based drug design targets the AT-rich malaria parasite: implications for antiparasite chemotherapy.

    abstract::Evaluation of: Woynarowski JM, Krugliak M, Ginsburg H: Pharmacogenomic analyses of targeting the AT-rich malaria parasite genome with AT-specific alkylating drugs. Mol. Biochem. Parasitol. 154(1), 70-81 (2007) [1] . The sequencing of the malaria genome sought to expose the parasite's ability to cause disease and ident...

    journal_title:Pharmacogenomics

    pub_type: 评论,杂志文章

    doi:10.2217/14622416.8.9.1267

    authors: Yanow SK,Purcell LA,Lee M,Spithill TW

    更新日期:2007-09-01 00:00:00

  • The pharmacogenetics of coumarin therapy.

    abstract::Vitamin K antagonists (coumarins) are widely-used oral anticoagulants for the prevention of venous thromboembolism and strokes. Wide inter-individual variation in dose response and frequent bleeds characterize the initiation of coumarin therapy. Over the past 10 years both genetic and nongenetic determinants of coumar...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/14622416.6.5.503

    authors: Voora D,McLeod HL,Eby C,Gage BF

    更新日期:2005-07-01 00:00:00

  • Cambridge Healthtech Institute's Third Annual Conference on Lab-on-a-Chip and Microarrays. 22-24 January 2001, Zurich, Switzerland.

    abstract::Cambridge Healthtech Institute's Third Annual Conference on Lab-on-a-Chip and Microarray technology covered the latest advances in this technology and applications in life sciences. Highlights of the meetings are reported briefly with emphasis on applications in genomics, drug discovery and molecular diagnostics. Ther...

    journal_title:Pharmacogenomics

    pub_type:

    doi:10.1517/14622416.2.1.73

    authors: Jain KK

    更新日期:2001-02-01 00:00:00

  • Pharmacogenetics of migraine: genetic variants and their potential role in migraine therapy.

    abstract::Migraine is a paroxysmal neurological disorder affecting up to 6% of males and 18% of females in the general population, and has been demonstrated to have a strong, but complex, genetic component. Genetic investigation of migraine provides hope that new targets for medications and individual specific therapy will be d...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/14622416.8.6.609

    authors: Fernandez F,Colson NJ,Griffiths LR

    更新日期:2007-06-01 00:00:00

  • Beta-adrenergic receptor polymorphisms and drug responses in asthma.

    abstract::Genetic variation in the beta 2-adrenoceptor and its associated proteins is common and therefore potentially relevant to the clinician. Several functional SNPs have been described but in vitro studies have yielded inconsistent results. Confounding due to the variable presence of other polymorphic alleles may be the ex...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.1517/14622416.3.2.173

    authors: Taylor DR,Kennedy MA

    更新日期:2002-03-01 00:00:00

  • Therapeutic targets and biomarkers identified in cancer choline phospholipid metabolism.

    abstract::Choline phospholipid metabolism is altered in a wide variety of cancers. The choline metabolite profile of tumors and cancer cells is characterized by an elevation of phosphocholine and total choline-containing compounds. Noninvasive magnetic resonance spectroscopy can be used to detect this elevation as an endogenous...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/14622416.7.7.1109

    authors: Glunde K,Serkova NJ

    更新日期:2006-10-01 00:00:00

  • Pharmacogenetics in clinical practice: how far have we come and where are we going?

    abstract::Recent years have seen great advances in our understanding of genetic contributors to drug response. Drug discovery and development around targeted genetic (somatic) mutations has led to a number of new drugs with genetic indications, particularly for the treatment of cancers. Our knowledge of genetic contributors to ...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.13.52

    authors: Johnson JA

    更新日期:2013-05-01 00:00:00

  • Gene expression profile analysis: an emerging approach to investigate mechanisms of genotoxicity.

    abstract::The response to stress triggers transcriptional activation of genes involved in cell survival and/or cell death. Thus, the monitoring of gene expression levels in large gene sets or whole genomes in response to various agents (toxicogenomics) has been proposed as a tool for investigating mechanisms of toxicity. Althou...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.1517/14622416.6.4.419

    authors: Aubrecht J,Caba E

    更新日期:2005-06-01 00:00:00

  • Clinical pharmacogenetics: how do we ensure a favorable future for patients?

    abstract::Currently, there is sufficient evidence for the use of pharmacogenetic information to optimize medication prescribing, but why has this information not been integrated into the drug prescribing process to improve patient care? A discussion about the major contributing factors that have limited the use of pharmacogenet...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs-2017-0192

    authors: Wiltshire T,Dong OM

    更新日期:2018-04-01 00:00:00

  • Genomic variants in the ASS1 gene, involved in the nitric oxide biosynthesis and signaling pathway, predict hydroxyurea treatment efficacy in compound sickle cell disease/β-thalassemia patients.

    abstract:AIM:Hemoglobinopathies exhibit a remarkable phenotypic diversity that restricts any safe association between molecular pathology and clinical outcomes. PATIENTS & METHODS:Herein, we explored the role of genes involved in the nitric oxide biosynthesis and signaling pathway, implicated in the increase of fetal hemoglobi...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.16.1

    authors: Chalikiopoulou C,Tavianatou AG,Sgourou A,Kourakli A,Kelepouri D,Chrysanthakopoulou M,Kanelaki VK,Mourdoukoutas E,Siamoglou S,John A,Symeonidis A,Ali BR,Katsila T,Papachatzopoulou A,Patrinos GP

    更新日期:2016-03-01 00:00:00

  • Strengths and weaknesses of pharmacogenetic studies of antipsychotic drugs: the potential value of the PEPs study.

    abstract::The successful application of pharmacogenetics in routine clinical practice is still a long way from becoming a reality. In order to favor the transfer of pharmacogenetic results to clinical practice, especially in psychiatry, these studies must be optimized. This article reviews the strengths and weaknesses that char...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,多中心研究,评审

    doi:10.2217/pgs.12.159

    authors: Mas S,Llerena A,Saíz J,Bernardo M,Lafuente A

    更新日期:2012-11-01 00:00:00

  • Requirements for comprehensive pharmacogenetic genotyping platforms.

    abstract::Recent research highlighted the large extent of rare variants in pharmacogenes and, on this basis, it was estimated that rare variants account for 30-40% of the functional variability in pharmacogenes. It has been proposed that comprehensive next-generation sequencing (NGS)-based sequencing of pharmacogenes could soon...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs-2016-0023

    authors: Lauschke VM,Ingelman-Sundberg M

    更新日期:2016-06-01 00:00:00

  • Applications of pharmacogenomics in general dental practice.

    abstract::The human oral cavity represents a complex ecology of approximately 500 microbial species existing as commensals, and interacting with human/host factors. Perturbation of this ecosystem can lead to diseases of the oral cavity. The oral cavity also acts as a mirror of complex systemic diseases. Unique challenges and op...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.1517/phgs.4.2.163.22626

    authors: Slavkin HC

    更新日期:2003-03-01 00:00:00

  • Economic evaluation of pharmacogenomic-guided warfarin treatment for elderly Croatian atrial fibrillation patients with ischemic stroke.

    abstract:BACKGROUND & METHODS:Economic evaluation in genomic medicine is an emerging discipline to assess the cost-effectiveness of genome-guided treatment. Here, we developed a pharmaco-economic model to assess whether pharmacogenomic (PGx)-guided warfarin treatment of elderly ischemic stroke patients with atrial fibrillation ...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,随机对照试验

    doi:10.2217/pgs.14.167

    authors: Mitropoulou C,Fragoulakis V,Bozina N,Vozikis A,Supe S,Bozina T,Poljakovic Z,van Schaik RH,Patrinos GP

    更新日期:2015-01-01 00:00:00

  • SULT4A1 haplotype: conflicting results on its role as a biomarker of antipsychotic response.

    abstract:AIM:Based on previous pharmacogenetic findings, we investigated the possible association between SULT4A1-1 haplotype and antipsychotic treatment response. MATERIALS & METHODS:Using Mixed Model Repeated Measures, we tested the relationship between SULT4A1-1 status (+carrier, -noncarrier) and clinical improvement (in Po...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.14.105

    authors: Wang D,Li Q,Favis R,Jadwin A,Chung H,Fu DJ,Savitz A,Gopal S,Cohen N

    更新日期:2014-01-01 00:00:00

  • Evidence for association of an ACCN1 gene variant with response to lithium treatment in Sardinian patients with bipolar disorder.

    abstract:AIMS:Bipolar disorder (BD) is a lifelong psychiatric illness characterized by manic and depressive episodes affecting 1-5% of the general population. Among mood-stabilizing treatments, lithium represents the mainstay in the therapeutic management of BD. However, besides the relatively high rate of excellent responders,...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.11.102

    authors: Squassina A,Manchia M,Borg J,Congiu D,Costa M,Georgitsi M,Chillotti C,Ardau R,Mitropoulos K,Severino G,Del Zompo M,Patrinos GP

    更新日期:2011-11-01 00:00:00

  • International warfarin genotype-guided dosing algorithms in the Turkish population and their preventive effects on major and life-threatening hemorrhagic events.

    abstract:AIM:To determine the accuracy of international warfarin pharmacogenetic algorithms developed on large multiethnic cohorts (comprising more than 1000 subjects) to predict therapeutic warfarin doses in Turkish patients. MATERIALS & METHODS:We investigated two Turkish warfarin-treated cohorts: patients with no history of...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.15.58

    authors: Karaca S,Bozkurt NC,Cesuroglu T,Karaca M,Bozkurt M,Eskioglu E,Polimanti R

    更新日期:2015-01-01 00:00:00

  • The genetics of fibromyalgia syndrome.

    abstract::Fibromyalgia syndrome (FMS) is a common chronic widespread pain syndrome mainly affecting women. Although the etiology of FMS is not completely understood, varieties of neuroendocrine disturbances, as well as abnormalities of autonomic function, have been implicated in its pathogenesis. The exposure of a genetically p...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/14622416.8.1.67

    authors: Buskila D,Sarzi-Puttini P,Ablin JN

    更新日期:2007-01-01 00:00:00

  • Influence of genetic polymorphisms in the glutamatergic and GABAergic systems and their interactions with environmental stressors on antidepressant response.

    abstract:AIM:To investigate the role of genetic polymorphisms in glutamatergic and GABAergic genes and their interactions with environmental stressors in antidepressant response. METHODS:A set of 114 SNPs of 34 glutamatergic and GABAergic genes, mainly in promoter and coding regions, were genotyped in 281 Chinese Han major dep...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.13.1

    authors: Pu M,Zhang Z,Xu Z,Shi Y,Geng L,Yuan Y,Zhang X,Reynolds GP

    更新日期:2013-02-01 00:00:00

  • Pharmacogenetic score predicts overall survival, progression-free survival and platinum sensitivity in ovarian cancer.

    abstract::Aim: To define the impact of polymorphisms in genes involved in platinum-taxane and estrogen activity in the outcome of platinum-based treated ovarian cancer patients (OCP). Patients & Methods: Two hundred and thirty OCP were analyzed for 124 germ-line polymorphisms to generate a prognostic score for overall survival ...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs-2020-0049

    authors: Gagno S,Bartoletti M,Romualdi C,Poletto E,Scalone S,Sorio R,Zanchetta M,De Mattia E,Roncato R,Cecchin E,Giorda G,Toffoli G

    更新日期:2020-09-01 00:00:00

  • Role of pharmacogenetics in busulfan/cyclophosphamide conditioning therapy prior to hematopoietic stem cell transplantation.

    abstract::Hematopoietic stem cell transplantation (HSCT) is a curative treatment for several malignant and nonmalignant disorders. Busulfan (Bu) and cyclophosphamide (Cy) are the most commonly used alkylators in high-dose pretransplant conditioning for HSCT; a treatment that is correlated with drug-related toxicity and relapse....

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs.12.185

    authors: Hassan M,Andersson BS

    更新日期:2013-01-01 00:00:00

  • Evaluation of a shared pharmacogenomics curriculum for pharmacy students.

    abstract:AIM:This national dissemination study evaluated pharmacy students' self-reported overall ability, self-efficacy and attitudes toward applying pharmacogenomics and perceptions of Pharmacogenomics Education Program, a shared pharmacogenomics curriculum. PATIENTS & METHODS:Following a series of train-the-trainer programs...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.14.181

    authors: Lee KC,Hudmon KS,Ma JD,Kuo GM

    更新日期:2015-01-01 00:00:00

  • Genome-wide association study identifies CAMKID variants involved in blood pressure response to losartan: the SOPHIA study.

    abstract:BACKGROUND:Essential hypertension arises from the combined effect of genetic and environmental factors. A pharmacogenomics approach could help to identify additional molecular mechanisms involved in its pathogenesis. AIM:The aim of SOPHIA study was to identify genetic polymorphisms regulating blood pressure response t...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.14.119

    authors: Frau F,Zaninello R,Salvi E,Ortu MF,Braga D,Velayutham D,Argiolas G,Fresu G,Troffa C,Bulla E,Bulla P,Pitzoi S,Piras DA,Glorioso V,Chittani M,Bernini G,Bardini M,Fallo F,Malatino L,Stancanelli B,Regolisti G,Ferri

    更新日期:2014-09-01 00:00:00

  • Warfarin and cytochrome P450 2C9 genotype: possible ethnic variation in warfarin sensitivity.

    abstract:INTRODUCTION:Warfarin is a widely prescribed, efficacious oral anticoagulant. S-warfarin, the more active form, is metabolized by the cytochrome P450 (CYP)2C9 enzyme. The aim was to evaluate the influence of two CYP2C9 functional polymorphisms (*2 and *3) on warfarin dose in African-Americans, an unstudied population a...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/14622416.8.3.217

    authors: Kealey C,Chen Z,Christie J,Thorn CF,Whitehead AS,Price M,Samaha FF,Kimmel SE

    更新日期:2007-03-01 00:00:00

  • The genomic response of skeletal muscle to methylprednisolone using microarrays: tailoring data mining to the structure of the pharmacogenomic time series.

    abstract::High-throughput data collection using gene microarrays has great potential as a method for addressing the pharmacogenomics of complex biological systems. Similarly, mechanism-based pharmacokinetic/pharmacodynamic modeling provides a tool for formulating quantitative testable hypotheses concerning the responses of comp...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.1517/14622416.5.5.525

    authors: Almon RR,DuBois DC,Piel WH,Jusko WJ

    更新日期:2004-07-01 00:00:00

  • Pharmacogenetics of chemotherapy efficacy in breast cancer.

    abstract::Large differences are observed in chemotherapy response between breast cancer patients, with a substantial part of this variability being explained by genetic factors. Polymorphisms in genes encoding drug-metabolizing enzymes, drug transporters and drug targets influence the pharmacokinetics and pharmacodynamics of th...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs.12.44

    authors: González-Neira A

    更新日期:2012-04-01 00:00:00